AlphAIAlphAI — Financial news for AI agents
investing.com$CBIO

Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright

H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy with a $36.00 price target, citing potential catalysts in 2027. The stock is currently trading at $13.94. The firm highlighted the company's antibody-drug conjugate pipeline and recent public offering raising $143.7 million. CBIO's balance sheet shows more cash than debt, a strength for a clinical-stage biotech.

Original reporting
investing.com
Published Oct 6, 2026, 12:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CBIO
Bullish
high confidence
Mentioned
$CBIO
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CBIOBullishHigh
01

Why it matters

The upgrade and capital raise provide immediate upside catalysts, but long‑term risk remains tied to trial outcomes.

02

Market read

Analyst upgrade and fresh financing create a short‑term bullish catalyst for CBIO, while the broader biotech sector may benefit from heightened interest in ADC platforms.

03

What to watch

Potential regulatory setbacks or trial failures could negate the upside.

Relevance 7/10Novelty 7/10Timing: today

Background

Crescent Biopharma is a clinical‑stage biotech developing antibody‑drug conjugates (ADCs) with CR‑003 and CR‑002 slated for 2027 data readouts.

Company-level read

Ticker impact

$CBIOBullishHigh confidence
Context

H.C. Wainwright upgraded Crescent Biopharma to Buy with a $36 target and the company completed a $143.7M public offering.

Expected impact

likely upward pressure as traders price in the buy rating and additional cash runway.

Evidence & confidence

Analyst upgrade provides a clear catalyst; the sizable raise improves balance sheet and funding for upcoming 2027 ADC trials.

Market effects

Sector

Positive for the broader ADC/biotech sector as the upgrade highlights pipeline potential.

Regional

U.S. biotech market may see modest buying interest.

Global

Limited; primarily affects Crescent Biopharma and peers.

Counterpoint

What could challenge this read

The upgrade may be premature given clinical data are still years away; valuation could be overstated.

Key entities

  • company
    Crescent Biopharma Inc.

    NASDAQ‑listed biotech developing ADCs.

  • analyst_firm
    H.C. Wainwright

    Issued the Buy upgrade and $36 price target.

Read at source← All news

Related articles

$CBIOMed

H.C. Wainwright reiterates Crescent Biopharma stock rating at buy

H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.

investing.com
$CBIOHighAI 8/10

Stifel reiterates Crescent Biopharma stock rating on pipeline progress

Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.

investing.com
$CBIOMed

Crescent Biopharma advances CR-001 combos, clears IND for CR-002 and sets mid‑2027 data timelines

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.

tradingview.com
$CBIOMed

Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x…

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care

SEC EDGAR 8-K